• +1-646-491-9876
    • +91-20-67278686

    Search

    Tyrosine Protein Kinase JAK2-Pipeline Review H1 2017

    Tyrosine Protein Kinase JAK2-Pipeline Review H1 2017

    • Report Code ID: RW0001834459
    • Category Pharmaceuticals
    • No. of Pages 123
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H1 2017

    Summary

    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 2, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myeloproliferative Disorders, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Atopic Dermatitis, Myelofibrosis, Asthma, Auto Inflammatory Disease, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Glioblastoma Multiforme (GBM) , Leukemias, Multiple Myeloma (Kahler Disease) , Myelodysplastic Syndrome, Post-Polycythemia Vera Myelofibrosis (PPV-MF) , Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Alopecia, Anaplastic Astrocytoma, B-Cell Leukemia, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL) , Dermatitis, Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) , Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD) , Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) , Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoma, Multiple Sclerosis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL) , Polycythemia Vera, Proliferative Diabetic Retinopathy (PDR) , Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL) , Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL) , Renal Failure, Respiratory Tract Inflammatory Disorders, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) , Thalassemia, Thrombocythemia Myelofibrosis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

    Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
    - The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    Aerie Pharmaceuticals Inc
    Aptose Biosciences Inc
    AstraZeneca Plc
    Bristol-Myers Squibb Company
    Celon Pharma SA
    CTI BioPharma Corp
    Eli Lilly and Company
    Genentech Inc
    Incyte Corp
    Japan Tobacco Inc
    Nerviano Medical Sciences Srl
    Nippon Shinyaku Co Ltd
    Novartis AG
    Simcere Pharmaceutical Group
    Theravance Biopharma Inc
    Tragara Pharmaceuticals Inc
    Vectura Group Plc
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
    AR-13154 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-1480 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    baricitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BVB-808 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CHZ-868 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CPL-407105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Inhibit JAK2 for Rheumatoid Arthritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JTE-052 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MA-2014 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NMSP-113 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NMSP-953 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NS-018 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pacritinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ruxolitinib phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAR-317461 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit JAK2 for Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TD-1473 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TD-3504 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TG-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VR-588 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
    Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
    Featured News & Press Releases
    Apr 14, 2017: U.S. FDA Issues Complete Response Letter For Baricitinib
    Apr 04, 2017: Aclaris Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Baricitnib for Hair Loss Disorders
    Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib)
    Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
    Feb 15, 2017: Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo
    Feb 13, 2017: European Commission Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis
    Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
    Jan 13, 2017: U.S. FDA Extends Review Period For Baricitinib, An Investigational Rheumatoid Arthritis Treatment
    Jan 09, 2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017
    Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
    Dec 30, 2016: Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi) in Graft-versus-Host Disease
    Dec 16, 2016: CHMP Recommends Approval of Lillys Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)
    Dec 06, 2016: PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting
    Dec 04, 2016: Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi (ruxolitinib)
    Nov 21, 2016: CTI BioPharma Announces data on Pacritinib at ASH Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Aerie Pharmaceuticals Inc, H1 2017
    Pipeline by Aptose Biosciences Inc, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by Bristol-Myers Squibb Company, H1 2017
    Pipeline by Celon Pharma SA, H1 2017
    Pipeline by CTI BioPharma Corp, H1 2017
    Pipeline by Eli Lilly and Company, H1 2017
    Pipeline by Genentech Inc, H1 2017
    Pipeline by Incyte Corp, H1 2017
    Pipeline by Japan Tobacco Inc, H1 2017
    Pipeline by Nerviano Medical Sciences Srl, H1 2017
    Pipeline by Nippon Shinyaku Co Ltd, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Simcere Pharmaceutical Group, H1 2017
    Pipeline by Theravance Biopharma Inc, H1 2017
    Pipeline by Tragara Pharmaceuticals Inc, H1 2017
    Pipeline by Vectura Group Plc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Dormant Products, H1 2017 (Contd..3) , H1 2017
    Discontinued Products, H1 2017
    Discontinued Products, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Aerie Pharmaceuticals Inc
    Aptose Biosciences Inc
    AstraZeneca Plc
    Bristol-Myers Squibb Company
    Celon Pharma SA
    CTI BioPharma Corp
    Eli Lilly and Company
    Genentech Inc
    Incyte Corp
    Japan Tobacco Inc
    Nerviano Medical Sciences Srl
    Nippon Shinyaku Co Ltd
    Novartis AG
    Simcere Pharmaceutical Group
    Theravance Biopharma Inc
    Tragara Pharmaceuticals Inc
    Vectura Group Plc

    Request for Sample

    Report Url https://www.reportsweb.com//tyrosine-protein-kinase-jak2-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//tyrosine-protein-kinase-jak2-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//tyrosine-protein-kinase-jak2-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments